Vmbook Online ordering

Icons

ICON plc (NASDAQ: ICLR) is a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Ireland and has operations in 37 locations around the world.

ICON provides a range of services including drug development, strategic consulting, clinical trials, data management, biostatistics, and regulatory affairs. The company's clients include large pharmaceutical companies, biotech firms, and medical device companies.

According to its Wikipedia page, ICON plc was founded in 1990 and has since grown to become one of the largest contract research organizations (CROs) in the world. As of 2021, the company has over 15,500 employees and reported annual revenues of $2.6 billion.

ICON's stock has performed well over the past five years, with a five-year cumulative total return of 185.1% as of February 2023. The company has also consistently exceeded analyst earnings estimates, with an earnings surprise percentage of 5.3% over the past four quarters.

In terms of growth, ICON has reported strong revenue growth in recent years, with a compound annual growth rate (CAGR) of 6.5% from 2017 to 2021. The company's net income has also grown at a CAGR of 12.3% over the same period.

ICON's strong financial performance has been driven by several factors, including the continued growth of the global pharmaceutical market, the increasing demand for outsourced drug development services, and the company's ability to win new contracts and expand its service offerings.

Overall, ICON plc is a well-established and financially robust company in the drug development services industry, with a strong track record of growth and profitability.